Yes i have asked the mods to delete my post...the 'fell over' bit was for another indication.
More accurate status for DMD is below:
The pharma giant also reported that ongoing discussions with the FDA have created a roadblock for their Phase III trial of a new gene therapy for Duchenne muscular dystrophy now dubbed fordadistrogene movaparvovec.
My view still stands - we won't see GT solution for DMD anytime soon.
FDA will make both Pfizer and Sarepta jump through some very expensive and time consuming hoops to prove GT safety and efficacy.
Sarepta, Roche and Pfizer need to look at a more practical solution as a bridge until GT is further refined...and safe.
Accumulate on weakness!
.
Pfizer hits brakes on DMD gene therapy, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
0.004(6.25%) |
Mkt cap ! $61.30M | |||
| Open | High | Low | Value | Volume |
| 6.6¢ | 7.1¢ | 6.5¢ | $198.2K | 2.885M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14845 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
6.8¢ |
Change
0.004 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 6.6¢ | 7.1¢ | 6.6¢ | 295714 | ||
| Last updated 15.58pm 26/04/2024 ? | |||||
| PER (ASX) Chart |